2021 American Association for Cancer Research (AACR) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the virtual AACR Annual Meeting April 10-15, 2021 and May 17-21, 2021.

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations

Oral Presentations

Date/Time	Title	ID
April 11 2:50 PM - 3:00 PM	Molecular dissection of chemotherapy response in triple negative breast cancer (TNBC) using microscaled proteogenomics DCTD Authors: Henry Rodriguez, Ana Robles	18
April 12 1:35 PM - 1:45 PM	Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC) DCTD Author: Malcolm Smith	LB008
May 17 9:45 AM - 10:45 AM	NCI Consortia Initiative and Resource: Proteomics and Proteogeomics DCTD Chair and Speakers: Ana I. Robles (C), Henry Rodriguez, Erika Kim, Justin Kirby, Ana I. Robles, Mehdi Mesri
May 21 9:45 AM - 10:45 AM	The Cancer Imaging Archive (TCIA) DCTD Speaker: John Freyman

Poster Presentations

Title and DCTD First Author	ID
Saturday, April 10 — 8:30 AM — 11:59 PM
LASSO-based protein signatures for survival prediction in human cancer cohorts Mariam Konate, BRP	160
SCLC-CellMiner: An Extensive Cell Line Genomic and Pharmacology Resource identifies a subgroup of small cell lung cancers sensitive to targeted therapies and immunotherapies	203
Sarcoma-CellMiner: An extensive resource for patient-derived sarcoma cell line epigenetics, genomics and pharmacology	212
A standard operating procedure for the curation of gene fusions	449
Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study	485
Germline cancer predisposition results from the National Cancer Institute — Children’s Oncology Group (NCI-COG) Pediatric MATCH Trial	631
A phase I trial of Triapine and Lutetium Lu 177 Dotatate in combination for well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	674
Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification	974
Combination screening of KRASG12C specific inhibitors with other targeted therapies in patient-derived multicellular tumor spheroids	1028
Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines	1072
Fostering engagement in biobanking and research through the NCI Cancer Moonshot℠ Biobank Participant and Provider Engagement Website Esmeralda Casas-Silva, CDP	2632
Comparison of PDMR cell line complex spheroid response and PDX response to trametinib Beverly Teicher, DTP	2644
Imaging characterization of NCI patient derived model repository (PDMR) xenografts Paula Jacobs, OD	3007
A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in the NCI PDXNet centers	3009
Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute’s patient-derived models repository Yvonne Evrard, FNLCR	3010
Patient-derived models of rare cancers in the National Cancer Institute’s patient-derived models repository Cindy Timme, FNLCR	3012
Applications of immunohistochemistry in characterization of patient derived xenograft models Lindsay Dutko, FNLCR	3015
Advancing PDX research through model, data, and bioinformatics with the PDXNet Portal	3017
Integrative genomics reveals IncRNAs associated with pediatric cancer	3028
Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models — a report from the pediatric preclinical testing consortium (PPTC)	3038
Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia	3039
Pan-cancer stemness defined by CPTAC proteogenomics guides personalized therapies	3113
Study of tumor heterogeneity and subclonality in primary pancreatic and metastatic sites from rapid autopsy patients in PDMR Li Chen, FNLCR	3139
Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors	CT115
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes	CT138
The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)	LB171
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor Copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models	LB252

Meet-the-Expert Presentations (Video Information)

Date/Time	Topic	Presenter
Thursday, May 6 1:00-1:30 PM	NCI-Cancer Diagnosis Program Initiatives, Funding Opportunities and Research Resources for Investigators	Aniruddha Ganguly, CDP
Monday, May 10 1:00-1:30 PM	The NCI National Clinical Laboratory Network	Tracy Lively, CDP
Tuesday, May 11 1:00-1:30 PM	NCI National Clinical Trials Network (NCTN) and Cooperative Human Tissue Network (CHTN) Biospecimens Available for the Cancer Research Community	Irina Lubensky and Rodrigo Chuaqui, CDP
Wednesday, May 12 1:00-1:30 PM	Funding Opportunities at Other ICs for Cancer Research	Sundar Venkatachalam, DTP